Eikonizo is a company headquartered in the United States.
Eikonizo develops brain-penetrant and peripherally-restricted small molecule inhibitors targeting HDAC6 to create disease-modifying therapies for neurodegenerative, cardiorenal, and other diseases by improving intracellular transport and proteostasis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.